Why This Landed on My Radar
Every independent practice has done this math: patients are paying cash-pay clinics and online vendors thousands a year for weight-loss injections - why not capture that in-house? It’s a fair question with a real upside and a few genuine landmines. Here’s the honest version of what it takes to do it right, and a reframe on where the value actually is.
First: Code What You Already Do, Correctly
Before you build anything new, most practices are under-capturing the obesity work they already do. The relevant coding (confirm against current CMS/AMA guidance, which updates annually):
- G0447 - face-to-face intensive behavioral therapy (IBT) for obesity, 15-minute sessions, in a primary-care setting. Medicare covers a tapering schedule (roughly weekly in month 1, biweekly months 2-6, monthly months 7-12 with documented progress) for patients with BMI ≥ 30, using the 5A’s framework (Assess, Advise, Agree, Assist, Arrange). G0473 is the group equivalent.
- CPT 99401-99404 - preventive medicine counseling (commercial payers).
- Diagnosis codes - E66.x (overweight/obesity), Z68.x (BMI), often paired with Z71.3 (dietary counseling).
- Documentation - BMI, risk factors, the lifestyle plan, time spent, and goals discussed. This is what makes the visit defensible.
This is legitimate, already-covered work most practices leave on the table.
The Compliance Landmines (Do Not Step on These)
- Do not prescribe unapproved “research peptides.” BPC-157, CJC-1295, TB-500, sermorelin and the rest are not FDA-approved, not on the 503A bulks list, and cannot be lawfully compounded today (Episode 7). “Removed from Category 2” earlier this year did not make them legal. Prescribing or dispensing them is direct enforcement and liability exposure.
- Be very careful with compounded GLP-1s. Now that the semaglutide and tirzepatide shortages are resolved, the legal basis for routine compounding has largely ended, and FDA is actively enforcing - 50+ warning letters to GLP-1 compounders in September 2025 alone, continuing into 2026 (Episode 6). Compounded retatrutide cannot be used at all - it’s an unapproved, misbranded new drug.
- Informed consent and duty to warn. Document the indication, the boxed warning and contraindications, the common and serious adverse effects, and that you screened for MTC/MEN2. The malpractice exposure in this space is concentrated in inadequate warning and inadequate documentation.
The Reframe: Value-Based Beats Cash-Pay
A cash-pay peptide “program” chases margin in the most compliance-fraught corner of this field. The bigger, cleaner opportunity is strategic use of FDA-approved GLP-1s in your existing panel - and it’s worth more under a value-based contract than a cash line ever will be. As Episode 8 lays out, GLP-1s are genuinely cost-effective (worth the health they buy) and the cost-offset concentrates in identifiable high-risk patients (established CVD, diabetic CKD). The practice that systematically identifies those patients, keeps them adherent, and documents the avoided events is building durable value - not just billing a visit.
What This Means for Your Practice
- Capture the obesity care you already deliver - G0447, the right diagnosis codes, real documentation.
- Stay on approved products. The unapproved-peptide and compounded-copy shortcuts are where the enforcement and liability live.
- Lead with informed consent and documentation - it’s your best malpractice protection.
- Think value, not cash margin. The high-risk-patient, approved-drug, adherence-supported strategy is the one that pays under VBC.
This is Episode 5 of Peptides in Primary Care. PayerVantage helps independent practices pinpoint which patients make GLP-1 therapy a value-based win under their specific contracts. [See how →]
Educational content for clinicians; not medical, legal, or coding advice. Confirm all coding against current CMS/AMA guidance. Current as of June 2026.